AGM Statement and Board Changes

Summary by AI BETAClose X

Craneware plc reported continued positive momentum at the start of FY26, driven by direct sales and a successful alliance with Microsoft, which is significantly growing the sales pipeline and fostering innovation. The company is investing in R&D, particularly in AI-enabled applications, and has rapidly launched a new product to support customers with the upcoming 340B drug rebate pilot program, mitigating financial risk and ensuring compliance. The Board confirmed that the Group is trading in line with market expectations, supported by its strong annuity SaaS model, balance sheet, recurring revenue, and cash generation, providing confidence in continued growth and long-term value creation.

Disclaimer*

Companies

Craneware (CRW)
UK 100

Latest directors dealings